Neuropathix Inc - ESG Rating & Company Profile powered by AI
The Disclosure rating covers 17 United Nations SDGs including: 'Zero Hunger', 'Sustainable Cities & Communities' and 'Life below Water'. This ESG assessment for Neuropathix Inc represents its reporting of the UN SDGs. The webpage is a zero-cost Environmental, Social and Governance analysis for Neuropathix Inc.
Neuropathix Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.4; made up of an environmental score of 0.0, social score of 1.6 and governance score of 2.7.
1.4
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 2372 | Yifan Pharmaceutical Co Ltd | 1.5 | Low |
| 2372 | iNtRON Biotechnology Inc | 1.5 | Low |
| 2416 | Neuropathix Inc | 1.4 | Low |
| 2416 | Aerpio Pharmaceuticals Inc | 1.4 | Low |
| 2416 | Anterogen Co Ltd | 1.4 | Low |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Neuropathix Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Neuropathix Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Neuropathix Inc report the average age of the workforce?
Sign up for free to unlockDoes Neuropathix Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Neuropathix Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Neuropathix Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Neuropathix Inc offer flexible work?
Sign up for free to unlockDoes Neuropathix Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Neuropathix Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Neuropathix Inc conduct supply chain audits?
Sign up for free to unlockDoes Neuropathix Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Neuropathix Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Neuropathix Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Neuropathix Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Neuropathix Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Neuropathix Inc disclose water use targets?
Sign up for free to unlockDoes Neuropathix Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Neuropathix Inc have a product recall in the last two years?
Sign up for free to unlockDoes Neuropathix Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Neuropathix Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Neuropathix Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Neuropathix Inc disclose parental leave metrics?
Sign up for free to unlockDoes Neuropathix Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Neuropathix Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Neuropathix Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Neuropathix Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Neuropathix Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Neuropathix Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Neuropathix Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Neuropathix Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Neuropathix Inc disclose its waste policy?
Sign up for free to unlockDoes Neuropathix Inc report according to TCFD requirements?
Sign up for free to unlockDoes Neuropathix Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Neuropathix Inc disclose energy use targets?
Sign up for free to unlockDoes Neuropathix Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Neuropathix Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Neuropathix Inc
These potential risks are based on the size, segment and geographies of the company.
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.